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BAG-1 (bcl-2-associated athanogene) enhances oestrogen receptor (ER) function and may influence outcome and response to
endocrine therapy in breast cancer. We determined relationships between BAG-1 expression, molecular phenotype, response to
tamoxifen therapy and outcome in a cohort of breast cancer patients and its influence on tamoxifen sensitivity in MCF-7 breast
cancer cells in vitro. Publically available gene expression data sets were analysed to identify relationships between BAG-1 mRNA
expression and patient outcome. BAG-1 protein expression was assessed using immunohistochemistry in 292 patients with invasive
ductal carcinoma and correlated with clinicopathological variables, therapeutic response and disease outcome. BAG-1-overexpressing
MCF-7 cells were treated with antioestrogens to assess its effects on cell proliferation. Gene expression data demonstrated a
consistent association between high BAG-1 mRNA and improved survival. In ERþ cancer (n¼189), a high nuclear BAG-1
expression independently predicted improved outcome for local recurrence (P¼0.0464), distant metastases (P¼0.0435), death
from breast cancer (P¼0.009, hazards ratio 0.29, 95% CI: 0.114–0.735) and improved outcome in tamoxifen-treated patients
(n¼107; P¼0.0191). BAG-1 overexpression in MCF-7 cells augmented antioestrogen-induced growth arrest. A high BAG-1
expression predicts improved patient outcome in ERþ breast carcinoma. This may reflect both a better definition of the hormone-
responsive phenotype and a concurrent increased sensitivity to tamoxifen.
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Breast cancer is a heterogeneous disease with considerable
variability in clinical outcome, the prognosis and management of
which is largely based on histopathological features accompanied
by established markers of hormone receptor status, oestrogen and
progesterone receptors (oestrogen receptor (ER), progesterone
receptor (PR)), and HER-2 amplification (Sorlie et al, 2001;
Goldhirsch et al, 2007). Oestrogen receptor-positive disease
comprises approximately 70% of cases and therapies targeting
oestrogen synthesis or the ER are the most effective treatments,
with adjuvant tamoxifen reducing the annual risk of recurrence
and death by up to 47 and 26% respectively (Early Breast Cancer
Trialists’ Collaborative Group, 2005) and reducing the risk of
contralateral disease by 50% (Fisher et al, 1998). However, the
benefits of treatment are limited by intrinsic or acquired
resistance, which occurs in approximately 40% of ERþ breast
cancers (Howell et al, 2005). New predictive biomarkers of
hormone responsiveness and disease outcome are needed to
improve selection of patients for optimal ‘targeted’ endocrine
therapy at an earlier stage in the disease process with potential
survival benefits. In addition, they may also identify key
mechanisms involved in antioestrogen resistance/sensitivity.
Gene expression profiling has identified intrinsic molecular
phenotypes of breast cancer that subclassify ERþ tumours into
two main subtypes that predict outcome: luminal A and B, which
can be distinguished by the presence of increased proliferation,
HER-2 amplification and a less favourable prognosis in the latter
group (Sorlie et al, 2001). Signatures that predict outcome in ERþ
disease treated with tamoxifen (Ma et al, 2004; Jansen et al, 2005;
Loi et al, 2008) have been useful in identifying potential new
predictive biomarkers. However, such molecular testing is
expensive and there is often little overlap between signatures
from different studies. Furthermore, translating these findings into
clinically useful biomarkers suitable for routine pathology practice
is a priority. Ideally, this would be performed using immuno-
histochemistry, which is more cost-effective and more easily
introduced within the existing infrastructure. However, this
approach is often limited by the lack of commercially available
antibodies for many of these genes.
BAG-1 (bcl-2-associated athanogene) is a pro-survival protein
that can influence diverse biological processes including nuclear
hormone receptor function, apoptosis, signal transduction and
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sprotein turnover (reviewed in Cutress et al (2002)). BAG-1 exists as
three protein isoforms. The specific ability of the long isoform,
BAG-1L (p50), which possesses a nuclear localisation sequence not
present in the other isoforms, to upregulate the transcriptional
activity of both ERa and ERb up to five-fold in MCF-7 breast
cancer cells (Cutress et al, 2003), is of potential functional and
prognostic significance. BAG-1 is expressed in most normal
human tissues (Takayama et al, 1998), and its overexpression
has been described not only in breast cancer, but also in other
human malignancies including squamous cell carcinoma of the
head and neck (Shindoh et al, 2000), chronic lymphocytic
leukaemia (Kitada et al, 1998) and prostate cancer (Maki et al,
2007), in which it is associated with a poor prognosis. However, its
role as a predictive marker in breast cancer has not been
established. Several studies have attempted to relate BAG-1 protein
expression to disease outcome with inconsistent results, which
may have been the result of low patient numbers, low rates of
ERþ tumours (ERþ rates of 35–52% rather than a currently
expected rate of B70%) and incomplete pathological, clinical and
treatment information. However, the improved prognosis asso-
ciated with a high BAG-1 expression has earlier been demonstrated
in three studies although with differences in subcellular localisa-
tion of BAG-1 expression that is, cytoplasmic (Turner et al, 2001),
nuclear (Cutress et al, 2003), and cytoplasmic or nuclear (Nadler
et al, 2008). More recently, BAG-1 featured as one of the 16 cancer-
specific genes included in the Oncotype Dx assay (Paik et al, 2004),
which predicts distant failure in ERþ, lymph node-negative
patients treated with tamoxifen using PCR of formalin-fixed
paraffin-embedded (FFPE) material. In addition, this assay has
also been used to predict the potential benefit of chemotherapy
(Paik et al, 2006) in this group of patients.
As ER-mediated regulation of cell growth, proliferation and
survival are key components of breast cancer development, the
role of BAG-1 as a predictive and prognostic marker in breast
cancer requires further investigation. Consequently, we aimed to
define the relationship of BAG-1 expression with outcome and
response to therapy in a large cohort of early breast cancer patients
of uniform histological type with well-documented treatment and
follow-up data.
MATERIALS AND METHODS
BAG-1 mRNA expression and outcome
Publically available gene expression data from two published
studies (van de Vijver et al, 2002; Naderi et al, 2007) of breast
cancer outcome were analysed to initially identify a potential
relationship between BAG-1 mRNA levels and prognosis. The
cohorts chosen for these analyses were of similar clinicopatholo-
gical composition to our clinical cohort. The study by Naderi et al
(2007) comprised 135 patients, 70% of whom were ERþ with a
median follow-up of 132 months (range 16–160 months). Data
were generated using Agilent Human 1A arrays, which were
available as raw scanner data files and sourced from Array Express
(http://www.ebi.ac.uk/) accession E-UCON-1. Using the limma R
package (R Development Core Team, 2007), background-sub-
tracted data were normalised by the global LOESS technique
applied to non-control spots only. To combine information from
duplicate dye-swap arrays, a linear model was fitted to the
normalised data using limma (Smyth, 2005). Model fit coefficients
for each sample were then used as final expression estimates,
expressed relative to a pooled reference RNA. The second data set,
sourced from van de Vijver et al (2002), comprised 295 patients,
76% of which were ERþ, with a median follow-up of 93.6 months
(range 0.6–220 months). Data were generated using Rosetta NKI-
spotted oligonucleotide arrays and were downloaded from http://
microarray-pubs.stanford.edu/wound_NKI/ explore.html as log2-
transformed values in a text table format. Raw data were directly
transferred to the final output file without further processing. One
BAG-1 probe set was available from each cohort and expression
data were analysed for frequency distribution of mRNA and its
association with patient outcome.
Patient characteristics
BAG-1 protein expression was assessed by immunohistochemistry
in tumours from a cohort of 292 patients diagnosed with invasive
ductal breast carcinoma and treated by a single surgeon (PC)
between February 1992 and August 2002. Formalin-fixed, paraffin-
embedded tissue was retrieved from St Vincent’s Public Hospital
(Sydpath) and St Vincent’s Private Hospital (Douglas Hanly Moir
Pathology), Sydney, Australia. All tumours were classified as
invasive ductal carcinoma of no special type and graded using
standardised histological criteria (Elston and Ellis, 1991). Lymph
node status was assessed by axillary sampling and histological
examination. Follow-up intervals were calculated from the date of
definitive procedure (biopsy/lumpectomy/mastectomy) to the date
of last-recorded follow-up (median 64 months, range 0–152
months). Patients less than 50 years of age with node-positive,
ER  tumours or tumours larger than 3cm received adjuvant
chemotherapy (cyclophosphamide, methotrexate and 5-fluorour-
acil or adriamycin and cyclophosphamide (AC)). Patients with
ERþ tumours who were more than 50 years of age received 5
years of tamoxifen therapy. Breast cancer-specific survival was
defined as date of definitive procedure to date of death due to
breast cancer. Patients who died of causes unrelated to breast
cancer were considered as censored at the time of death. Deaths
from unknown causes were excluded from analysis of disease-
specific survival. Recurrences were confirmed by imaging and/or
histology. Locoregional recurrences were defined as of the
ipsilateral breast, chest wall, axilla or supraclavicular fossa. Distant
relapses and metastases were defined as disease in the lungs, liver,
brain or distant lymph nodes. These data were obtained from
annual review of patient files or cancer registry data. Tissue
microarrays (TMAs) of FFPE tumour tissue blocks were
constructed with approximately 80 1mm cores per slide. Each
patient was represented by two to six 1mm cores. Prior approval
for this study was obtained from the Human Research Ethics
Committee of St Vincent’s Hospital, Sydney (HREC SVH H94/080,
HREC 06336 SVH H00 036).
Immunohistochemistry
Four-micron sections were cut from each TMA, mounted on
SuperFrost
s Plus glass slides and baked for 2h at 791C, then
dewaxed by passage through xylene (two 5min washes), cleared
and rehydrated in graded alcohol (100, 95 and 70%) ending in a
distilled water wash. Antigen retrieval was performed using DAKO
solution (pH 6.0) (s1699; DAKO, Carpentaria, CA, USA) in a
pressure cooker (DAKO Pascal Decloaker) for 60s, followed by
cooling gently for 15min in a running water bath. Following a
thorough wash in distilled water, endogenous peroxidase activity
was eliminated with 3% hydrogen peroxide for 5min. Slides were
incubated with BAG-1 mouse monoclonal antibody raised against
full-length human BAG-1 protein (clone 3.10G3E2; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) at a dilution of 1:50 for
45min at room temperature. Following buffer wash, detection
employed DAKO Envisionþ mouse secondary reagent (DAKO)
for 30min at room temperature, followed by DAKO DABþ
chromagen (DAKO) for 10min. Slides were then rinsed in water
and counterstained with haematoxylin, dehydrated through graded
ethanol, cleared in xylene and mounted. Normal colon was
employed as a control tissue that showed positive staining in
basal crypt cell nuclei and negative staining in the muscularis
mucosae. A further negative control substituted isotype-matched
mouse IgG1 at 1:100 in place of the BAG-1 monoclonal antibody.
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stained using the following antibodies: ER, 1:100 (clone 6F11;
DAKO); PR, 1:200 (clone PgR 636; DAKO); CK5/6, 1:80 (clone
MAB1602; Chemicon International, Temecula, CA, USA); and
EGFR, 1:100 (clone H11; DAKO). HER-2 FISH was assessed in the
Australian National Reference Laboratory (Department of Patho-
logy, St Vincent’s Hospital, Sydney) using the Vysis PathVysion
HER-2 DNA dual-colour probe kit. An HER2:chromosome 17
ratio42.2 was classified as HER2 amplification.
All assessments of immunohistochemical staining were
performed by observers blinded to the clinical and molecular data
and patient outcome. Nuclear and cytoplasmic staining for BAG-1
was assessed by an experienced breast pathologist (EKAM) and
described in terms of the intensity (0: negative, 1þ: weak, 2þ:
moderate and 3þ: strong) and percentage of cells staining
positive. From these indices, a simplified ‘H score’ (i.e.,
intensity percentage of positive nuclei) was calculated for each
core and a mean and median score for each parameter calculated
for each tumour (range of two to six cores per patient). Oestrogen
receptor and PR (both double scored) were assessed as positive if
they had a simplified H score of 410. CK5/6 and EGFR (both
double scored) were assessed as positive if there was any positive
cytoplasmic or membranous staining present at any intensity.
Definition of intrinsic molecular phenotype of breast
cancer
This was assessed immunohistochemically using criteria similar to
those recently described by Cheang et al (2008) but using FISH to
determine HER-2 status as follows: luminal A¼ERþ and/or
PRþ, HER-2 ; luminal B¼ERþ and/or PRþ, HER-2þ;
HER-2¼ER  and PR , HER-2þ; basal-like¼ER ,P R  ,
HER-2 , CK5/6þ and/or EGFRþ; unclassified¼negative for all
five markers.
Cell culture studies
The human ERþ breast cancer cell line, MCF-7, was routinely
maintained in RPMI-1640 medium supplemented with 5% foetal
calf serum, 10mgml
 1 insulin and 2.92mgml
 1 glutamine under
standard conditions. A cDNA insert encoding human BAG-1 (cat
no. SC107955; OriGene Technologies Inc., Rockville, MD, USA)
was cloned into the retroviral vector pMSCV-IRES-GFP (Caldon
et al, 2008). MCF-7 cells transiently expressing the murine
ecotropic receptor were infected with BAG-1 retrovirus as
described earlier (Debnath et al, 2003). Green fluorescent
protein-positive cells were sorted to homogeneity by flow
cytometry. Cell lysates were collected as described earlier (Prall
et al, 1997). Subsequent western blotting using a BAG-1 antibody
(3.10G3E2; Clone Chemicon International Inc., Billerica, MA, USA)
confirmed BAG-1 expression. b-Actin (Sigma, St Louis, MO, USA)
was used as a loading control.
S-phase analysis
Exponentially growing MCF-7 cells expressing BAG-1 or vector-
alone control were treated with 1mmoll
 1 4-hydroxytamoxifen
(Sigma) or 10nmoll
 1 ICI 182780 (7a-[9-(4,4,5,5,5-pentafluoro-
pentylsulphinyl) nonyl] estra-1,3,5,(10)-triene-3,17b-diol), which
was a kind gift from Dr Alan Wakeling (Astra-Zeneca Pharma-
ceuticals, Alderly Park, Cheshire, UK), or vehicle (ethanol) for
24h. Cells were harvested and Sphase was analysed by propidium
iodide staining and flow cytometry.
Statistical analyses
Statistical analyses were performed using Statview 5.0. Software
(Abacus Systems, Berkeley, CA, USA). A P-value o0.05 was
accepted as statistically significant. BAG-1 mRNA and protein
expression and its association with clinicopathological variables
and intrinsic molecular phenotype of breast cancer were tested by
applying the w
2-test of association in contingency tables. Kaplan–
Meier and Cox proportional hazards model were used for
univariate analysis and the latter for multivariate analyses. Those
factors that were prognostic in univariate analysis were then
assessed in a multivariable model to identify factors that were
independently prognostic and those that were the result of
confounding variables.
RESULTS
BAG-1 mRNA expression and outcome
To identify an association between BAG-1 gene expression levels
and patient outcome, we examined two published breast cancer
gene expression data sets. A frequency distribution of BAG-1
mRNA expression was used to apply serial cut points using
sequential Kaplan–Meier analysis (log-rank test) to minimise the
P-value and maximise the difference in survival between the two
groups of high and low expressions. Using this approach,
statistical significance was assessed for death using univariate
Kaplan–Meier and Cox proportional hazards analysis (Table 1).
The Wound/NKI data set of 295 patients contained a high BAG-1
expression group of 234 patients (79.3%), which was associated
with improved prognosis in Cox and Kaplan–Meier univariate
analysis (P¼0.0005, Table 1A and Figure 1A). High BAG-1
expression was not significant in a multivariate model that
incorporated standard clinicopathological variables (Table 1B).
Table 1 Association between BAG-1 mRNA expression and breast cancer outcome
High BAG-1 expression n (%) HR 95% CI P-value
(A) Cox univariate analysis for high BAG-1 expression from publicly available gene expression data sets
Wound/NKI
(van de Vijver et al, 2002) 234/295 (79.3%) 0.439 0.277–0.697 0.0005
Naderi
(Naderi et al, 2007) 108/135 (80%) 0.412 0.212–0.843 0.0151
(B) Cox multivariate analysis for the Wound cohort (n¼295)
Grade42 2.266 1.361–3.774 0.0017
Size420mm 1.678 1.039–2.710 0.0343
ER positive 0.549 0.323–0.933 0.0267
HER-2 positive 2.319 1.267–4.244 0.0064
BAG-1 high 0.911 0.530–1.567 0.7363
CI¼confidence interval; ER¼oestrogen receptor; HR¼hazards ratio.
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group of 108 patients (80%), again associated with a favourable
outcome in Kaplan–Meier (P¼0.0120) and Cox univariate
analyses (P¼0.0151, Table 1A and Figure 1B) but not in
multivariate analysis (data not shown). Using these cut points
to define high and low expression, further analyses were conducted
to determine association between high BAG-1 expression and
clinicopathological parameters. In the Wound cohort, high BAG-1
was associated with ERþ,P Rþ, low histological grade and HER-2
negativity (Po0.0001) but there was no association with tumour
size (P¼0.0862) or lymph node status (P40.999). Similarly, the
Naderi cohort also showed positive associations between high
BAG-1 expression and ERþ (P¼0.0014), HER-2 negativity
(P¼0.0044) and low histological grade (P¼0.0061) but not with
tumour size or lymph node status (P¼0.081 and P¼0.106,
respectively). These findings support an association of high BAG-1
expression with a luminal A phenotype and improved survival.
Immunohistochemical analysis of BAG-1 protein
expression in normal breast tissue and invasive ductal
carcinoma
Representative immunohistochemistry staining patterns and
intensities of BAG-1 are illustrated in Figure 2A–I. Similar
patterns of staining were observed in normal terminal duct lobular
units adjacent to cancer (n¼24, 20 patients) and in reduction
mammoplasty specimens (n¼20, 14 patients). Nuclear staining
was observed in all cases, with a mean of 54% of epithelial cells
(range 10–90%) showing weak-to-strong (1–3þ) intensity.
Cytoplasmic staining was also present in 63% of cases with a
range of 0–100% of cells showing 1 or 2þ staining.
In our cohort of 292 patients, 276 invasive ductal carcinomas
were available for BAG-1 analysis due to loss of some tissue cores
during processing of the TMAs. Staining was of variable intensity,
which ranged from negative to strong (0–3þ) and demonstrated
both cytoplasmic and nuclear staining in keeping with the known
subcellular localisation of the various BAG-1 isoforms (Cutress
et al, 2002). There was, however, no direct correlation between
nuclear and cytoplasmic expression when modelled as continuous
variables (R¼0.476). Sixteen out of 276 cases (5.7%) showed no
nuclear staining, whereas 26 cases (9.4%) showed no cytoplasmic
staining. When assessed for the percentage of positively staining
nuclei, there appeared to be two distinct sub-populations, which
could be dichotomised at a cutoff value of 40% positively staining
nuclei at any intensity (Figure 2J). Cytoplasmic staining displayed
a similar pattern (Figure 2K), with most tumours showing at least
weak positivity but again with two distinct populations that could
be identified using a 40% cutoff value. By applying the selected cut
point of 440% mean nuclear staining, we defined 78% (214 out of
276) of the cohort as ‘high’ BAG-1 expressers and 22% (62 out of
276) as ‘low’ BAG-1 expressers. This cut point appeared to
represent a real split in the protein expression data, which matched
that observed from our analysis of the mRNA expression levels.
This distribution was not apparent in the frequency distribution
of nuclear ‘H’ scores. Consequently, we adopted the percentage
of positively staining nuclei as the index for further analysis of
association with outcomes.
Correlation of BAG-1 expression with clinicopathological
features and intrinsic molecular subtype
The relationship between nuclear and cytoplasmic expression of
BAG-1 and standard clinicopathological features of the disease are
summarised in Table 2A. High expression of BAG-1 showed a
significant positive correlation with low histological grade, ER and
PR positivity (Po0.0001) and was correlated negatively with HER-2
amplification status (P¼0.001) and the triple-negative phenotype
(Po0.0001). These findings were apparent for both nuclear and
cytoplasmic staining at a cut point of 40% positivity of any intensity,
but with a higher degree of statistical significance for nuclear
staining. High nuclear BAG-1 expression was also strongly correlated
with a luminal A intrinsic phenotype: 73% (154 out of 211) of BAG-1
‘high’ were luminal A (Po0.0001, w
2-test), but there was no
correlation with luminal B (P¼0.956). A strong negative correlation
w a so b s e r v e dw i t ht h eH E R - 2( 5 % ,1 1o u to f2 1 3B A G - 1h i g ha r eo f
HER-2 phenotype, Po0.0001) and the basal-like phenotype (7%, 14
out of 213 BAG-1 high are basal-like, Po0.0001).
BAG-1 expression and outcome
In the whole cohort (n¼276), high nuclear BAG-1 expression was
associated with a favourable prognosis for all measures of outcome
in univariate analysis: local recurrence (P¼0.002), distant
metastases (Po0.0001) and breast cancer-specific death
(Po0.0001, Table 3A and Figure 3). Furthermore, high nuclear
BAG-1 expression was also an independent predictor of outcome
in multivariate analysis for distant metastases (P¼0.0455,
Table 3B) but not for local recurrence or death. To assess whether
BAG-1 was an independent prognostic variable and not the result
of confounding by other variables, Cox proportional hazards
models were constructed with step-wise removal of redundant
variables until resolution. The resolved multivariate model is
presented in Table 3C. High cytoplasmic expression of BAG-1 was
also associated with improved outcome for local recurrence
(P¼0.0092), distant metastases (P¼0.0013) and death
(P¼0.0046) on Kaplan–Meier univariate analysis, but was not
significant in multivariate analysis.
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Figure 1 Relationship between BAG-1 mRNA expression and patient outcome. Kaplan–Meier analysis (log-rank test) for breast cancer-specific death in
the Wound/NKI (A) and Naderi (B) cohorts. High BAG-1 (K); low BAG-1 (J).
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we next assessed the association with outcome in the ERþ and
ER  subgroups. Within ER-positive tumours (n¼189), high
nuclear BAG-1 expression was an independent predictor of
outcome in both univariate and multivariate analyses (Figure 3
and Table 3D). In the multivariate model employed, which
incorporated standard pathological indicators of outcome: tumour
size, grade, nodal status, PR and HER-2, the resolved model, which
eliminates redundant variables, retained HER-2, PR and BAG-1
(Table 3E). Cytoplasmic staining was not significant in univariate
analysis in this group of patients. In the smaller subgroup of
ER-negative tumours (n¼85), nuclear staining of BAG-1 was not
associated with any index of outcome in univariate analysis. As our
data demonstrated a strong relationship between high BAG-1
expression, ER positivity and the luminal A phenotype, we
assessed whether BAG-1 expression was associated with a
differential response to adjuvant tamoxifen therapy. The data
reported in Figure 3 demonstrate that patients treated with
tamoxifen (n¼107), whose tumours had a high nuclear BAG-1
expression, showed an improved outcome in univariate Kaplan–
Meier analysis for local recurrence (P¼0.032), distant metastases
(P¼0.019) and breast cancer-specific death (P¼0.038).
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Figure 2 Representative images of BAG-1 immunohistochemistry. (A) Negative staining in high-grade invasive ductal carcinoma (IDC),  400. (B) Weak
(1þ) nuclear staining in low-grade IDC,  400. (C) Moderate (2þ) nuclear and weak (1þ) cytoplasmic staining in low-grade IDC, with strong nuclear
staining in an adjacent normal duct (arrow). (D) Moderate (2þ) cytoplasmic and negative nuclear staining in high-grade IDC. (E) Strong (3þ) nuclear and
moderate (2þ) cytoplasmic staining in high-grade IDC. (F) Strong (3þ) nuclear and weak (1þ) cytoplasmic staining, weak nuclear staining in normal duct
(arrow),  400. (G) Strong 3þ nuclear staining. (H) Moderate nuclear staining in normal acini. (I) Normal colon, control tissue, which shows moderate
positive nuclear staining in basal crypt cell nuclei and negative staining in mucularis mucosae. Frequency distribution of BAG-1 nuclear (J) and cytoplasmic (K)
staining using immunohistochemistry in 276 invasive ductal carcinomas. There are two distinct populations that can be dichotomised using a cut point of 40%
(arrow), which segregates the cohort into high- and low-expressing subgroups.
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in vitro
To provide some potential mechanistic insights into the relation-
ship between high BAG-1 expression and improved outcome in
ERþ tamoxifen-treated patients, we assessed the effect of BAG-1
overexpression on oestrogen/antioestrogen sensitivity in ERþ
MCF-7 breast cancer cells. A pool of high BAG-1-expressing MCF-
7 cells was isolated and overexpression of the three major protein
isoforms (BAG-1L, BAG-1M and BAG-1S) was confirmed by
western blotting (Figure 4A). BAG-1 was also overexpressed in a
panel of ERþ breast cancer cell lines compared with normal and
immortalised breast epithelial cells (Figure 4A), and thus this high-
expressing pool of MCF-7 cells represented an appropriate model
to study the biological consequences of BAG-1 overexpression and
was used for all further analyses.
MCF-7 BAG-1 cells were treated with 1mmoll
 1 4-hydroxyta-
moxifen, 10nmoll
 1 ICI 182780 or vehicle for 24h and the
percentage of S-phase cells determined by flow cytometry.
Antioestrogen-induced cell cycle arrest was enhanced in MCF-7
BAG-1 cells compared with vector control (Figure 4B). Treatment
of MCF-7 BAG-1 cells with the pure oestrogen antagonist ICI
182780 (Po0.005) or the active metabolite of tamoxifen,
4-hydroxytamoxifen (Po0.05), in replicate experiments demon-
strated a significantly enhanced cell cycle arrest as measured by a
decrease in Sphase compared with control cells (Figure 4C).
DISCUSSION
The recent characterisation of molecular phenotypes of breast
cancer defines biological subgroups, independent of histological
Table 2 Clinicopathological features of the breast cancer cohort and association with BAG-1 expression
Nuclear BAG-1 Cytoplasmic BAG-1
Positive Negative P-value Positive Negative P-value
(A) Clinicopathological characteristics and associations with BAG-1 expression
Age
450 135 39 0.979 135 39 0.252
o50 79 23 85 17
Grade
1 and 2 133 17 o0.0001 129 21 0.005
38 1 4 5 9 1 3 5
Size
420mm 81 31 0.086 82 30 0.027
o20mm 133 31 138 26
Nodal status
Positive 90 30 0.424 98 22 0.429
Negative 121 32 119 34
HER-2
Positive 31 20 0.001 32 19 0.001
Negative 180 40 184 36
ER
Positive 169 20 o0.0001 166 23 o0.0001
Negative 44 41 52 33
PR
Positive 146 13 o0.0001 141 18 o0.0001
Negative 67 49 78 38
CK5/6
Positive 19 14 0.003 23 10 0.127
Negative 195 48 197 46
Triple negative
Positive 25 23 o0.0001 31 17 0.0039
Negative 187 37 186 38
(B) Treatment and survival data n (%)
Endocrine therapy 144/292 (49.3)
Chemotherapy 111/292 (38.0)
Endocrine and chemotherapy 71/292 (24.3)
Recurrences 75/292 (25.7)
Distant metastases 68/292 (23.3)
Deaths 67/292 (22.9)
Breast cancer-specific deaths 52/292 (17.8)
5-year disease-free survival 74.0%
5-year metastasis-free survival 76.8%
5-year breast cancer-specific survival 86.0%
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stype, which provides a further insight into the disease at a
functional level. Luminal A cancers defined by the presence of ER
and/or PR positivity and HER-2 negativity form a favourable
prognostic group. However, further defining this group may
provide new insights into the underlying biology of oestrogen
sensitivity/resistance and provide clinically useful markers for
routine clinical practice. This study demonstrates that a high
BAG-1 expression identifies a good prognosis group of cancers
with a luminal A phenotype, which may have enhanced therapeutic
sensitivity to tamoxifen.
We first addressed the question of identifying an association
between BAG-1 mRNA expression levels and patient outcome in
two independent cohorts, which are broadly equivalent to our
validation cohort in terms of clinicopathological characteristics.
Using serially determined cut points, we identified two populations
of patients with high and low BAG-1 expressions, which correlated
with patient outcome. Thus, the high BAG-1 mRNA expression,
found within the top 80% of patients, is associated with a
favourable outcome. Correspondingly, the frequency distribution
of immunohistochemically detected BAG-1 protein expression in
our clinical cohort identifies two distinct subgroups of patients of
similar proportions to those identified in the gene expression
profiling analyses. High BAG-1 protein expression, defined as
greater than 40% positive nuclear staining of any intensity,
identified 78% of patients with a good prognosis. The predictive
value of high BAG-1 expression was greatest in ERþ cancer in
which a high nuclear expression was an independent predictor of
prognosis for local recurrence, distant metastases and death.
Furthermore, for breast cancer-specific death, BAG-1 expression
was of superior predictive power to tumour grade, tumour size and
lymph node status. This group of patients has a strong positive
correlation with a luminal A phenotype and low histological grade,
which suggests that BAG-1 may be a useful surrogate marker of
intact ER signalling and identifies those tumours maintaining a
luminal A-differentiated phenotype. Therefore, BAG-1 is a marker
with potentially useful prognostic applications in ERþ disease.
Outcome studies, published earlier, of BAG-1 expression using
immunohistochemistry have shown inconsistent results but with a
trend towards improved prognosis with high expression levels.
However, its role as a predictive biomarker has not yet been fully
defined or adequately validated. The first published study (Tang
et al, 1999) of 140 patients included both early and metastatic
disease, ER status was unknown in 38% of patients and only 35%
of patients were ERþ. Consequently, ER and PR were excluded
from multivariate analysis, which showed that an elevated nuclear
BAG-1 expression was associated with shorter disease-free and
overall survival, although BAG-1 was not significant in univariate
analysis. These findings were not replicated in a subsequent study
by the same group of investigators (Tang et al, 2004). The second
study of 122 patients (Turner et al, 2001) consisted predominantly
of pre-menopausal patients (mean age, 54 years), only 41% of
whom had ERþ cancers, and lymph node status was unknown in
48% of cases. In addition, well-documented prognostic indicators,
such as tumour size, grade, ER, PR and HER-2, were not significant
Table 3 Cox univariate and multivariate analyses
n (%) HR 95% CI P-value
(A) Whole-cohort clinicopathological variables (n¼292), univariate analysis of breast cancer-specific death
Age450 184/292 (63) 1.427 0.799–2.551 0.229
Grade42 132/291 (45) 3.100 1.865–5.163 o0.0001
Size420mm 117/291 (40) 2.730 1.678–4.443 o0.0001
LN positive 125/289 (43) 3.968 2.346–6.774 o0.0001
HER-2 positive 51/273 (18) 2.459 1.463–4.134 0.0007
ER positive 192/280 (68) 0.395 0.243–0.642 0.0002
PR positive 161/282 (57) 0.238 0.140–0.406 o0.0001
BAG-1 high 214/276 (78) 0.364 0.222–0.598 o0.0001
(B) Whole-cohort (n¼276) distant metastases, Cox multivariate analysis
Grade42 1.398 0.751–2.567 0.2948
Size420mm 1.564 0.937–2.610 0.0873
LN status 3.372 1.934–5.880 o0.0001
HER-2 1.853 1.066–3.220 0.0287
ER 0.990 0.525–1.868 0.9745
PR 0.405 0.212–0.776 0.0064
BAG-1 high 0.559 0.317–0.989 0.0455
(C) Whole-cohort distant metastases, Cox multivariate analysis, resolved model
LN status 3.597 2.097–6.168 o0.0001
HER-2 1.973 1.158–3.361 0.0125
PR 0.329 0.186–0.584 0.0001
BAG-1 high 0.586 0.344–0.998 0.0493
(D) ER+ (n¼189) breast cancer-specific death, Cox multivariate analysis
Grade42 1.529 0.600–3.896 0.3730
Size420mm 1.053 0.428–2.591 0.9100
LN status 1.471 0.571–3.795 0.4250
HER-2 5.578 2.036–15.286 0.0008
PR 0.293 0.119–0.721 0.0076
BAG-1 high 0.290 0.114–0.735 0.0090
(E) ER+ breast cancer-specific death, Cox multivariate analysis, resolved model
HER-2 6.725 2.7–16.644 o0.0001
PR 0.239 0.104–0.547 0.0007
BAG-1 high 0.302 0.122–0.744 0.0093
CI¼confidence interval; ER¼oestrogen receptor; HR¼hazards ratio.
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sin univariate analysis. In this study, elevated cytoplasmic BAG-1
expression was associated with improved prognosis in a multi-
variate model that included ER, BCL-2 and stage. In a more
homogeneous and representative cohort of early breast cancer,
Cutress et al (2003) described improved prognosis in univariate
analysis with high nuclear, but not high cytoplasmic, BAG-1
expression in a cohort of 138 patients, 60% of whom were ERþ.
All patients were treated with surgery and endocrine therapy
without chemotherapy. The largest and the most recent study of
517 patients (Nadler et al, 2008) used image analysis-based
assessment of immunofluorescent staining and found that both
high nuclear and cytoplasmic expression of BAG-1 was associated
with improved prognosis in the whole cohort and in lymph node-
positive patients only in univariate analysis, with a strong
correlation with ER, PR and Bcl-2. However, again in this study,
only 52% of patients were ERþ, with a predominance of large
tumours (59%42cm), and details on histological grade and
treatment were not available. Two other studies were unable to
identify any association with outcome in patients treated with
hormonal therapy (Townsend et al, 2002) or in a cohort with
advanced breast cancer treated with chemotherapy (Sjostrom et al,
2002). There are many possible explanations for these discordant
findings: differences in the composition of the clinical cohorts,
incomplete clinical information, different antigen retrieval
methods, differing monoclonal antibodies used in the detection
of BAG-1 and divergent cut points used to determine a high or low
expression. This study, therefore, confirms the findings described
earlier of improved prognosis with high nuclear BAG-1 expression
described by Cutress et al (2003) and represents a detailed analysis
of BAG-1 expression and its potential relationship with therapeutic
responsiveness in a large cohort of uniform histological type with
well-documented clinical outcome.
The finding of improved responsiveness to tamoxifen and better
patient outcome associated with a high expression of BAG-1, a
pro-survival antiapoptotic protein, is somewhat counter-intuitive
but is mirrored by several studies identifying the overexpression of
BCL-2, a major target of BAG-1, also being consistently associated
with improved prognosis in low-grade ERþ tumours (Callagy
et al, 2006) and also in patients treated with tamoxifen (Linke et al,
2006). Furthermore, the strong relationship between high nuclear
BAG-1 expression and improved patient outcome reported by
Cutress et al (2003) emanated from a cohort of tamoxifen-treated
patients. BAG-1, BCL-2 and ER feature among the 16 cancer-
related genes of the Oncotype Dx assay (Paik et al, 2004), which
predicts distant failure in ERþ lymph node-negative patients
treated with tamoxifen. The derived recurrence-score algorithm,
which is largely weighted towards proliferation-related genes,
assigns a negative value to the BAG-1 mRNA expression level, in
turn supporting our observation of improved prognosis with high
expression level. Several other gene expression profiling studies
have identified signatures predictive of outcome in ERþ disease
treated with tamoxifen (Ma et al, 2004; Jansen et al, 2005; Loi et al,
Whole cohort ER+ ER+ treated with tamoxifen
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Figure 3 Relationship between nuclear BAG-1 protein expression by immunohistochemistry and patient outcome. Kaplan–Meier analyses (log-rank test)
for (A) local recurrence, (B) distant metastases and (C) breast cancer-specific death in the whole cohort, ERþ subgroup and ERþ patients treated with
tamoxifen stratified by high (K) and low (J) BAG-1 expression.
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s2008). BAG-1 did not feature among genes within these signatures,
although there is often a limited overlap in signatures between
studies (Miller, 2007). Interestingly, an expression profiling study
(Cleator et al, 2006) of pre-treatment biopsies from 40 patients
treated with AC chemotherapy identified BAG-1, BCL-2 and ER
among a diverse group of 178 genes overexpressed in sensitive
tumours. Thus, the potential role of BAG-1 as a predictive marker
of therapeutic responsiveness to both endocrine and chemother-
apy requires further investigation. This is best performed within
the context of randomised clinical trials and these studies are
ongoing.
The BAG-1 gene is located on chromosome 9p12 and is
expressed as three protein isoforms generated through alternative
initiation sites from a single mRNA (Packham et al, 1997). The
overexpression of BAG-1 has been described in several breast
cancer cell lines (Takayama et al, 1998; Brimmell et al, 1999), with
the three isoforms demonstrating differing intracellular localisa-
tions: BAG-1L is predominantly nuclear, BAG-1S is predominantly
cytoplasmic and BAG-1M is present in both the cellular compart-
ments (Brimmell et al, 1999). This differential subcellular
localisation of BAG-1 isoforms is altered under different experi-
mental conditions, possibly representing a regulatory mechanism
for protein activity: BAG-1M relocalises from the cytoplasm to the
nucleus following heat shock (Zeiner et al, 1999) and when bound
to the glucocorticoid receptor, possibly downregulating the
receptor (Schneikert et al, 1999). Nuclear-to-cytoplasmic reloca-
lisation of BAG-1M has also been observed during epidermal and
neuronal differentiation and during breast epithelial involution,
both in vitro and in vivo (Takayama et al, 1998; Schorr et al, 1999;
Kermer et al, 2002). BAG-1 possesses a range of pro-survival
properties through its ability to interact with diverse downstream
target molecules, originally described by its ability to bind to and
enhance the activity of the antiapoptotic protein BCL-2 mediated
by its binding to the heat-shock proteins HSP70 and HSC70
(Takayama et al, 1995). Differential staining and subcellular
localisation of the isoforms have not been investigated in the
normal breast or breast cancer and are impaired by the absence of
isoform-specific antibodies, all current studies in breast detecting
‘total’ BAG-1 expression. The mechanism of overexpression of
BAG-1 in breast cancer is also not known although in prostate
cancer it is amplified in 7.4% of hormone-refractory cancers (Maki
et al, 2007). Our data with normal and malignant breast epithelial
cell lines confirm overexpression in ERþ carcinoma cell lines
compared with normal epithelial cells. The BAG-1S isoform
appeared to be preferentially overexpressed, but there was
evidence for elevated expression of all three isoforms in a cell
line-specific manner. The relative contribution of the respective
isoforms to the relationships reported here must await further
studies with isoform-specific antibodies.
A key target of BAG-1 is ERa, which when bound by the BAG-1L
isoform increases its transcriptional activity by up to five-fold in
MCF-7 cells (Cutress et al, 2003). The ability of high nuclear BAG-1
expression to predict improved outcome in ERþ cancer and also
in those treated with tamoxifen is of potential mechanistic
importance as it suggests that it may have a role in responsiveness
to adjuvant endocrine therapy. In our subgroup of ERþ patients
treated with tamoxifen (n¼107), high BAG-1 expression predicted
improved prognosis, which may indicate sensitivity to therapy or
possibly a better definition of a good prognostic luminal A group
of patients. To address the question of whether BAG-1 expression
could confer enhanced sensitivity to antioestrogen treatment in
vitro, we analysed cell cycle arrest in BAG-1-overexpressing MCF-7
cells. The data presented here demonstrate a significant increase in
sensitivity to the induction of cell cycle arrest by both tamoxifen
and the pure steroidal antioestrogen ICI 182780.
As antioestrogen therapy, targeted at oestrogen synthesis
(aromatase inhibitors), or the ER (tamoxifen), is the single most-
effective treatment for women with hormone receptor-positive
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Figure 4 Effects of modulating BAG-1 expression on antioestrogen
sensitivity in MCF-7 breast cancer cells. (A) Immunoblot analysis of cell
lysates from MCF-7 retrovirally infected pools stably overexpressing BAG-1
wild type, two normal breast epithelial and six ERþ breast cancer cell lines.
b-Actin was used as a loading control. Each of the three major BAG-1
protein isoforms are indicated: BAG-1L, BAG-1M and BAG-1S. (B)
Representative DNA histograms of MCF-7 cells stably overexpressing
BAG-1 compared with control cells after treatment with 10nmoll
 1 ICI
182780 or vehicle for 24h. Differences in scale are due to slight differences
in the number of events recorded. (C) Proliferating MCF-7 cells stably
overexpressing BAG-1 were treated with 1mmoll
 1 4-hydroxytamoxifen,
10nmoll
 1 ICI 182780 or vehicle for 24h. Cells were harvested and
Sphase was analysed by propidium iodide staining and flow cytometry. The
decrease in Sphase was graphed as fold change relative to vehicle-treated
vector control cells. The bar histograms represent the mean±s.e.m. for
replicate samples from five independent experiments. *Po0.05;
**Po0.005.
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sdisease, the ability to predict likely success or failure of these
therapies would enable potential alternative therapeutic strategies
to be targeted to a group of patients most likely to fail on
tamoxifen or aromatase therapy up-front or at an earlier stage in
treatment, which may result in improved outcome. The ability of
BAG-1 to predict responsiveness to antioestrogen therapy now
merits further investigation by examining the relationship between
expression and response in large randomised clinical trials of
endocrine therapy in ERþ patients.
In summary, we have demonstrated that the high BAG-1
expression is associated with the luminal A phenotype, is an
independent predictor of outcome and may indicate enhanced
responsiveness to tamoxifen in ERþ invasive ductal carcinoma.
These effects may be related to the ability of BAG-1 overexpression
to confer increased sensitivity to antioestrogens in vitro. These
findings suggest that BAG-1 immunohistochemistry may have a
role in a routine pathology setting as a marker for better defining
luminal A breast cancers and as a therapeutic response marker for
ER-targeted therapy with tamoxifen or aromatase inhibitors.
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